On the afternoon of May 28, Tian Lipu, former Director of the National Intellectual Property Administration (CNIPA), visited Zhejiang Tianyuan Biotechnology Co., Ltd. for research and inspection. Huang Bisheng, Chairman of the company and President of the Ningbo Intellectual Property Association, together with Zhu Youwu, Group Chief Administrative Officer, Jiao Mingming, General Manager, and other senior executives, warmly received him and accompanied him throughout the visit.

      Director Tian Lipu and his delegation first toured the Tianyuan Biotechnology science and technology exhibition hall. Chairman Huang Bisheng gave a detailed report on the company's development strategy and planning, as well as the major scientific and technological innovation achievements it has made in recent years. Group Chief Administrative Officer Zhu Youwu highlighted the company's notable strengths in intellectual property layout, the building of core technological barriers, and the deep integration of industry, academia, and research. The delegation then went into the laboratory to observe an on-site demonstration of "beating cardiomyocytes" derived from iPS cell-induced differentiation. Director Tian expressed high appreciation for the company's ability to overcome key technical challenges in cell preparation and to drive the translation of research achievements.

      At the subsequent symposium, General Manager Jiao Mingming first gave a comprehensive report on the company's basic operations and its market translation pathway. Then, Dr. Chen Junjie and Dr. Liu Guangcheng, core researchers of the company, delivered in-depth technical presentations on "Cutting-edge R&D Achievements in iPS Cells" and "Novel Cell Culture Methods," respectively, showcasing Tianyuan Biotechnology's hardcore technological strength in the regenerative medicine track.

      After hearing the reports, Director Tian Lipu fully affirmed the innovative vitality and scientific research foundation that Tianyuan Biotechnology has demonstrated in the biopharmaceutical field. He noted that Tianyuan Biotechnology drives its development through scientific and technological innovation and focuses on major clinical needs such as heart failure treatment, having made positive progress in cutting-edge fields including iPSC technology and cell-based drug development—reflecting the company's sense of responsibility in tackling key core technologies. Intellectual property is an important safeguard for scientific and technological innovation, and he expressed the hope that Tianyuan Biotechnology will continue to strengthen its intellectual property strategic layout, transform technological advantages into industrial advantages, firmly pursue the development path of the health industry, and enhance public well-being through the power of science and technology.

      On behalf of the company, Chairman Huang Bisheng expressed sincere gratitude to Director Tian Lipu for his care and guidance. He stated that Tianyuan Biotechnology will take this opportunity to continue increasing R&D investment, deepen the building of its intellectual property system, accelerate the R&D process of AI + iPSC heart failure therapeutic drugs, serve public health with a higher level of scientific and technological innovation, live up to the mission of the times, and contribute more Tianyuan strength to the building of a "Healthy China."

      Participants in the research visit included Chen Chao, Qian Long, and Yang Yishu from the Ningbo Intellectual Property Protection Center, and Li Yingchun from the Ningbo Intellectual Property Association.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a platform-based biopharmaceutical enterprise driven by AI + iPSC technology and dedicated to developing drugs for heart failure treatment. With its iPS seed cell bank, tumor cell bank, and HLA compatibility matching system as cornerstones, the company has built a full-chain R&D platform covering cell reprogramming, disease model construction, and candidate drug validation. Leveraging the policy advantages of Hainan's "Medical Special Zone," the company has opened up the "last mile" of clinical translation; through its regional network of facilities, it has achieved integrated operations spanning collection, preparation, R&D, and application; and with a closed-loop marketing ecosystem, it connects medical institutions, research platforms, and end users.